OS Therapies Granted End Of Phase 2 Meeting By Us FDA For OST-HER2 Program In The Prevention Or Delay Of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Refinitiv阅读少于1分钟
OS Therapies Inc 
OSTX:
OS THERAPIES GRANTED END OF PHASE 2 MEETING BY US FDA FOR OST-HER2 PROGRAM IN THE PREVENTION OR DELAY OF RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA
OS THERAPIES INC - MEETING EXPECTED TO OCCUR IN Q3 2025
OS THERAPIES INC - TO SEEK ROLLING REVIEW FOR BLA SUBMISSION
OS THERAPIES INC - COMPANY ELIGIBLE FOR PRIORITY REVIEW VOUCHER IF APPROVED BEFORE SEPT 30, 2026
登录或创建永久免费帐户以阅读此新闻